Compare Stocks: EQ, PROK, EIKN, and ARTV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$11.19 +0.5%	$10.57	$2.22 ▼ $14.53	$543.90M	2.18	281,957 shs	168,576 shs
EIKN Eikon Therapeutics	$10.86 -0.9%	$10.64	$7.90 ▼ $17.40	$593.65M	N/A	503,212 shs	238,685 shs
EQ Equillium	$2.21 -0.5%	$2.48	$0.76 ▼ $3.54	$140.77M	1.81	440,534 shs	225,911 shs
PROK ProKidney	$2.01 +4.7%	$1.68	$1.30 ▼ $3.48	$580.46M	1.7	1.22 million shs	1.22 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	-1.59%	-6.78%	+0.54%	+62.48%	+250.00%
EIKN Eikon Therapeutics	-3.69%	-4.86%	+14.64%	+22.32%	+1,095,999,900.00%
EQ Equillium	-1.33%	-9.39%	-1.77%	-24.49%	+18.72%
PROK ProKidney	+0.52%	+5.49%	+17.79%	+6.67%	-18.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$11.19 +0.5%	$10.57	$2.22 ▼ $14.53	$543.90M	2.18	281,957 shs	168,576 shs
EIKN Eikon Therapeutics	$10.86 -0.9%	$10.64	$7.90 ▼ $17.40	$593.65M	N/A	503,212 shs	238,685 shs
EQ Equillium	$2.21 -0.5%	$2.48	$0.76 ▼ $3.54	$140.77M	1.81	440,534 shs	225,911 shs
PROK ProKidney	$2.01 +4.7%	$1.68	$1.30 ▼ $3.48	$580.46M	1.7	1.22 million shs	1.22 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	-1.59%	-6.78%	+0.54%	+62.48%	+250.00%
EIKN Eikon Therapeutics	-3.69%	-4.86%	+14.64%	+22.32%	+1,095,999,900.00%
EQ Equillium	-1.33%	-9.39%	-1.77%	-24.49%	+18.72%
PROK ProKidney	+0.52%	+5.49%	+17.79%	+6.67%	-18.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	2.83	Moderate Buy	$39.00	248.53% Upside
EIKN Eikon Therapeutics	2.38	Hold	$25.00	130.20% Upside
EQ Equillium	2.91	Moderate Buy	$7.57	242.60% Upside
PROK ProKidney	2.67	Moderate Buy	$12.00	497.01% Upside

Current Analyst Ratings Breakdown

Latest EQ, PROK, EIKN, and ARTV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	EQ Equillium	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/21/2026	EIKN Eikon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/14/2026	EIKN Eikon Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underperform	$5.00 ➝ $4.00
8/11/2026	EQ Equillium	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/3/2026	EIKN Eikon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
7/21/2026	ARTV Artiva Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/21/2026	EQ Equillium	Clear Str Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/13/2026	EQ Equillium	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
7/13/2026	EQ Equillium	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/10/2026	PROK ProKidney	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/25/2026	PROK ProKidney	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	$250K	2,188.32	N/A	N/A	$7.11 per share	1.57
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	$8.61 per share	N/A
EQ Equillium	$41.10M	3.41	N/A	N/A	$0.88 per share	2.51
PROK ProKidney	$890K	682.77	N/A	N/A	($2.92) per share	-0.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$83.86M	-$3.30	N/A	N/A	N/A	N/A	-53.86%	-48.16%	11/11/2026 (Estimated)
EIKN Eikon Therapeutics	-$324.25M	-$4.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EQ Equillium	-$22.40M	-$0.20	N/A	N/A	N/A	N/A	-41.15%	-38.29%	11/12/2026 (Estimated)
PROK ProKidney	-$68.99M	-$0.55	N/A	N/A	N/A	-10,288.39%	N/A	-27.39%	11/9/2026 (Estimated)

Latest EQ, PROK, EIKN, and ARTV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	EIKN Eikon Therapeutics	-$1.61	-$1.63	-$0.02	-$1.63	N/A	N/A
8/13/2026	Q2 2026	EQ Equillium	-$0.0540	-$0.04	+$0.0140	-$0.04	N/A	N/A
8/10/2026	Q2 2026	PROK ProKidney	-$0.14	-$0.15	-$0.01	-$0.15	$0.19 million	$0.15 million
8/6/2026	Q2 2026	ARTV Artiva Biotherapeutics	-$0.6251	-$0.63	-$0.0049	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	24.16	24.16
EIKN Eikon Therapeutics	N/A	9.89	9.89
EQ Equillium	N/A	23.40	23.40
PROK ProKidney	N/A	8.36	8.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
EIKN Eikon Therapeutics	N/A
EQ Equillium	27.05%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	1.80%
EIKN Eikon Therapeutics	N/A
EQ Equillium	17.84%
PROK ProKidney	39.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	48.89 million	48.01 million	N/A
EIKN Eikon Therapeutics	384	54.17 million	N/A	N/A
EQ Equillium	40	63.41 million	52.10 million	Not Optionable
PROK ProKidney	3	302.32 million	181.91 million	Optionable

EQ, PROK, EIKN, and ARTV Headlines

Recent News About These Companies

ProKidney (NASDAQ:PROK) Stock Price Up 7.6% - Should You Buy?

September 4 at 2:19 PM | marketbeat.com

ProKidney Corp. (PROK) Options Chain - Yahoo Finance

August 26, 2026 | finance.yahoo.com

Brian Jg Pereira Sells 229,338 Shares of ProKidney (NASDAQ:PROK) Stock

August 20, 2026 | marketbeat.com

ProKidney (NASDAQ:PROK) Director Sells 222,948 Shares

August 20, 2026 | marketbeat.com

ProKidney (NASDAQ:PROK) Director Sells 222,949 Shares

August 20, 2026 | marketbeat.com

ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)

August 14, 2026 | seekingalpha.com

ProKidney (PROK) Receives a Hold from Morgan Stanley

August 14, 2026 | theglobeandmail.com

ProKidney (PROK) Receives a Hold from Morgan Stanley

August 14, 2026 | theglobeandmail.com

What is HC Wainwright's Estimate for ProKidney Q3 Earnings?

August 13, 2026 | marketbeat.com

ProKidney (PROK) Gets a Buy from Guggenheim

August 12, 2026 | theglobeandmail.com

ProKidney FY2030 EPS Estimate Decreased by HC Wainwright

August 12, 2026 | marketbeat.com

ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates

August 10, 2026 | zacks.com

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

August 10, 2026 | manilatimes.netM

ProKidney (NASDAQ:PROK) Releases Earnings Results, Misses Estimates By $0.01 EPS

August 10, 2026 | marketbeat.com

ProKidney Cell Therapy Thwarts Onerous Dialysis

July 30, 2026 | bloomberg.com

ProKidney Corp. (PROK) Latest Stock News & Headlines - Yahoo Finance

July 14, 2026 | finance.yahoo.com

ProKidney Corp (NASDAQ: PROK) - Share Price and Research

July 13, 2026 | intelligentinvestor.com.auI

What Makes ProKidney Corp (NASDAQ:PROK) Stand Out on Nasdaq Composite?

July 9, 2026 | kalkinemedia.comK

Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path

June 17, 2026 | insidermonkey.com

ProKidney names first chief technology officer as kidney therapy nears pivotal trial readout

June 2, 2026 | bizjournals.com

ProKidney Appoints Kenneth Locke as Chief Technical Officer

June 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EQ, PROK, EIKN, and ARTV Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$11.19 +0.06 (+0.54%)

As of 04:00 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Eikon Therapeutics NASDAQ:EIKN

$10.86 -0.10 (-0.91%)

As of 04:00 PM Eastern

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

Equillium NASDAQ:EQ

$2.21 -0.01 (-0.45%)

As of 04:00 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

ProKidney NASDAQ:PROK

$2.01 +0.09 (+4.69%)

As of 04:00 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EQ, PROK, EIKN, and ARTV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EQ, PROK, EIKN, and ARTV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EQ, PROK, EIKN, and ARTV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EQ, PROK, EIKN, and ARTV Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

Eikon Therapeutics NASDAQ:EIKN

Equillium NASDAQ:EQ

ProKidney NASDAQ:PROK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EQ, PROK, EIKN, and ARTV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EQ, PROK, EIKN, and ARTV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EQ, PROK, EIKN, and ARTV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EQ, PROK, EIKN, and ARTV Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

Eikon Therapeutics NASDAQ:EIKN

Equillium NASDAQ:EQ

ProKidney NASDAQ:PROK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools